Journal of Clinical & Experimental Pharmacology

Pharmacutical scale and green process for the synthesis of anticancer drug Pomalidomide

Joint Event on 11^th International Conference and Exhibition on Pharmacology and Ethnopharmacology & International Conference on Pharmaceutical Oncology

July 18-19, 2018 | Atlanta, USA

Reza Hosseinpour

Tofigh Darou Research and Engineering Company, Iran

Posters & Accepted Abstracts: Clin Exp Pharmacol

Abstract:

Pomalidomide (PML), chemically (RS)-4-amino-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, is a small molecule analog of thalidomide developed by Celgene Corporation for the treatment of hematological and connective tissue diseases by oral administration. It is a potent second-generation oral immunomodulatory agent with antineoplastic activity, showing significant activity in multiple myeloma patients with disease refractory to lenalidomide and bortezomib. We develop a new route for the preparation of pomalidomide on the pharmaceutical scale and polymorphic form based on Celgene Corporation. The synthetic procedure starts from 4-nitroisobenzofuran-1,3-dione and 3-aminopiperidine-2,6-dione hydrochloride via a 2 step reaction resulting in a total yield of 95% with a high HPLC purity of 99.98%.